Martin Shkreli Quotes

If my drug Ragaglitazar had been successful, we would have been getting royalties of thousands of crore rupees every year.

In general, drug companies are reasonably good at developing new treatments, and there's also a lot of good in the industry.

Cadila, India's sixth-largest drugmaker by sales, spent $250 million developing Lipaglyn, a new chemical entity or new discovery, and aims to spend another $150 million to $200 million to launch the drug outside India.

If you look at the world's top 50 drugs being sold today, they are being marketed and sold by companies that did not invent them. I respect patents. I'll pay a royalty. But I shouldn't be denied the right to produce drugs for poor people at reasonable prices.

While I recognize the great value and importance of prescription drugs and strongly support a continued U.S. focus on pharmaceutical research and development, our nation's seniors cannot be asked to subsidize the drug costs of other wealthy industrialized nations any longer.

Pharmaceutical companies are enjoying unprecedented profits and access with this Administration. Yet the Republicans' prescription drug plan for seniors has been a colossal failure, and over 43 million Americans wake up every morning without health insurance.

The pharmaceutical industry is spending $1 billion more each year on marketing and lobbying than it does on developing new and better drugs.

I would say that the pharmaceutical industry is hyper-competitive from a global perspective.

When you work in the pharmaceutical industry you realize that there's a lot out of people's control, and there's ways that people can be helped.

I don't like protecting pharmaceutical industries and increasing their profits and making our drugs cost more. If the U.S. Democrats could get rid of those problems I'd be much happier.

There's always going to be the need for new medications, better medications.

It's wrong to put the drug lobby's interests ahead of older Americans.

Internet pharmacies return to consumers the choice promised by supporters of the 1938 Food, Drug and Cosmetic Act. That law established federal requirements for drug safety and labeling but exempted prescription medicines from the labeling rules.

Now, what tends to happen is that the stories get hyped. And the medicines are not quite as revolutionary and as dramatic as they seem to be. But, certainly, various phases of this problem are being attacked by the pharmaceutical companies.

I keep encouraging the pharmaceutical companies to put more money into R&D.

It's time to stop defending a system that is clearly in dire need of reform, stop issuing reports and setting up new roadblocks, and start providing Americans with prescription drugs that are both safe and affordable.

If you go to the FDA with a drug that's only meant to treat 50 people, and it's a 95 percent cure rate, you'll get your drug approved.

It's easy to complain that pharmaceutical companies place profits over people and apparently care more about hair loss than TB. However, many in the pharmaceutical industry would be glad for the opportunity to reorient their research toward medicines that are truly needed, provided only that such research is financially sustainable.

I'd like to focus on my life on creating new medicines for people who are suffering from rare disease.

I believe that life-saving, essential drugs should be freely available and the innovator should be paid a suitable royalty payment for his invention.

While American taxes pay for much of the research and development that goes into creating the new, life-saving drugs, American consumers continue to subsidize the cost of the drugs for consumers across the world.

My priorities are to make sure we get the prescription drug bill, that we fund the research in NIH adequately, and that we fund the Center for Disease Control adequately.

The United States has an active pharmaceutical industry that has brought huge benefits to the U.S. public. Most Americans, who benefit from these advances, have little understanding of how difficult it is to create an important new medical therapy and make it available to improve public health.

We don't argue if drug companies create drugs that can cure humans and charge lots of money for them, even though we all have these diseases. It will be pretty hard to make a different argument for genes.

No pharmaceutical company is making money by selling biological knowledge - they make money by selling chemicals. So getting as much of that knowledge as possible into the efficiency of the Web-commerce world is going to make it faster to find those chemicals.